News from janssen r A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Dec 12, 2014, 12:15 ET

Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium

 Janssen Research & Development, LLC (Janssen) today announced the presentation of data at the San Antonio Breast Cancer Symposium...

Dec 10, 2014, 08:05 ET
Dec 10, 2014, 08:02 ET
Janssen Logo.  (PRNewsFoto/Janssen Pharmaceutical Companies)

Neue auf der ASH-Tagung vorgestellte Nachbeobachtungsdaten für IMBRUVICA® (Ibrutinib) belegen längerfristige Wirksamkeit bei Patienten mit chronischer lymphozytischer Leukämie und Mantelzelllymphom

Die Originalsprache dieser Pressemitteilung ist Englisch. Übersetzungen ins Deutsche, Französische und Spanische werden von PR Newswire...

Dec 08, 2014, 21:33 ET

IMBRUVICA® (ibrutinib) Long-term Follow-up Data in Patients Living with Relapsed/Refractory Mantle Cell Lymphoma Show Almost Half Alive at Two Years

 New data presented today at the American Society of Hematology (ASH) Annual Meeting in San Francisco, CA, suggest the current safety and...

Dec 08, 2014, 21:05 ET

IMBRUVICA® (ibrutinib) Shows Sustained Progression-Free Survival in Patients with High-Risk Chronic Lymphocytic Leukemia with Genetic Mutation

Results from the Phase 2 RESONATE™-17 (PCYC-1117) study show IMBRUVICA® (ibrutinib) was associated with an 82.6 percent...

Dec 05, 2014, 08:00 ET

Janssen Teams Up with the American Diabetes Association to Take On Type 2 Diabetes

Janssen Pharmaceuticals, Inc. (Janssen) today announced a collaboration with the American Diabetes Association (Association) to launch Teaming Up...

Dec 01, 2014, 03:00 ET
Janssen Logo.  (PRNewsFoto/Janssen Pharmaceutical Companies)

Solicitud enviada a la EMA para ampliar las indicaciones terapéuticas para IMBRUVICA® (ibrutinib), a fin de incluir el tratamiento de la macroglobulinemia de Waldenström

- Este comunicado de prensa está originalmente escrito en inglés. PR Newswire proporciona las traducciones en alemán, francés...

Dec 01, 2014, 03:00 ET
Janssen Logo.  (PRNewsFoto/Janssen Pharmaceutical Companies)

Zulassungsantrag an die EMA im Hinblick auf die Erweiterung der therapeutischen Indikation von IMBRUVICA® (ibrutinib) zur Behandlung von Morbus Waldenström

- Die Originalsprache dieser Pressemitteilung ist Englisch. Übersetzungen ins Deutsche, Französische und Spanische werden von PR...

Nov 24, 2014, 16:30 ET

Janssen Submits New Drug Application for YONDELIS® (trabectedin) to U.S. FDA for the Treatment of Patients with Advanced Soft Tissue Sarcoma

 Janssen Research & Development, LLC (Janssen) has submitted a New Drug Application (NDA) for YONDELIS® (trabectedin) to the U.S. Food...

Nov 19, 2014, 09:00 ET

Janssen Submits New Drug Application to U.S. FDA for Three-Month Paliperidone Palmitate

Janssen Research & Development, LLC (Janssen) today announced the submission of a New Drug Application (NDA) for three-month atypical...

Nov 18, 2014, 06:00 ET

Janssen reicht Antrag auf Zulassung von SIMPONI® für nicht-radiografische axiale Spondyloarthritis in der Europäischen Union ein

 Janssen Biologics B.V. (Janssen) gab heute bekannt, man habe eine Typ II-Variation bei der Europäischen Arzneimittelagentur auf Zulassung...

Nov 18, 2014, 06:00 ET

Janssen dépose une demande en vue de l'approbation de SIMPONI® dans l'Union européenne pour le traitement de la spondylarthrite axiale sans signe radiographique

 Janssen Biologics B.V. (Janssen) a annoncé aujourd'hui qu'une variation de type II avait été déposée auprès de...

Nov 13, 2014, 08:45 ET

U.S. FDA Approves Supplemental New Drug Applications for Once-Monthly Long-Acting Therapy INVEGA® SUSTENNA® (paliperidone palmitate) for the Treatment of Schizoaffective Disorder

Janssen Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) approved the supplemental New Drug Applications...

Nov 07, 2014, 19:06 ET
Janssen Logo.

Janssen Highlights its Hepatitis C Clinical Development Program in Advance of 2014 American Association for the Study of Liver Diseases (AASLD) Annual Meeting

Janssen R&D Ireland (Janssen) highlights its hepatitis C (HCV) clinical development program in advance of The Liver Meeting®, the Annual...

Nov 06, 2014, 09:54 ET

Janssen to Demonstrate Breadth of Oncology Portfolio with 41 Clinical Data Presentations at the 2014 American Society of Hematology (ASH) Annual Meeting

Janssen Research & Development, LLC (Janssen) will present new data across more than eight disease areas at the 56th American Society of...

Nov 06, 2014, 03:00 ET

Janssen Collaborates for Continued Evaluation of Multidrug-Resistant Tuberculosis Treatment Regimens with SIRTURO® (bedaquiline)

Janssen Research & Development, LLC (Janssen) today announced a collaboration with the International Union Against Tuberculosis and Lung...

Nov 05, 2014, 16:48 ET
OLYSIO(R) (simeprevir) Logo

OLYSIO® (simeprevir) Gains Additional FDA Approval as Once-Daily, All-Oral Interferon- and Ribavirin-Free Treatment Option in Combination with Sofosbuvir for Adults with Genotype 1 Chronic Hepatitis C Infection

Janssen Therapeutics, Division of Janssen Products, LP (Janssen) announced the U.S. Food and Drug Administration (FDA) has approved OLYSIO®...

Oct 27, 2014, 08:00 ET
Sunny Anderson, celebrity cook, television host and ulcerative colitis patient

Celebrity Cook Sunny Anderson Teams Up With Janssen And Crohn's & Colitis Foundation Of America To Launch Educational Campaign

Janssen Biotech, Inc. and the Crohn's & Colitis Foundation of America (CCFA) announced today the launch of Get Your Full Course, an educational...